ArticleTheranostics2023
OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
Abstract read
In one paragraph
Article in Theranostics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the frontiers: a bibliometric perspective on t cell-based immunotherapy in pancreatic cancer since the twenty-first century.Journal of cancer research and clinical oncology · 2025Pooled it
- Oncolytic virus therapy for hepatocellular carcinoma: A bibliometric analysis of research landscapes, hotspots, and clinical transformation trends from 2000 to mid-2025.Human vaccines & immunotherapeutics · 2026Review
- Clinical Progress in Virotherapy: Application and Future Prospects in Head and Neck Cancer.International journal of molecular sciences · 2026Review
- Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses.Experimental hematology & oncology · 2026Review
- T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Identification of prognostic genes and development of a risk model for pancreatic cancer based on hypoxia- and lipid metabolism-related genes.Discover oncology · 2026Article
- Multistage responsive microneedle delivery system loaded oncolytic virus for topical therapy of melanoma.Acta pharmaceutica Sinica. B · 2026Article
- Immunogenic tumor cell death and T-cell-derived IFN-γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy.Cell reports. Medicine · 2026Article
- Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma.Pharmaceutics · 2026Review
- Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy.Molecular cancer · 2026Review
- Microbiota in cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026Review
- Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- The role and mechanism of neutrophils in oncolytic virus therapy.Experimental biology and medicine (Maywood, N.J.) · 2026Review
- Prognostic immunological implications of OX40L expression in the tumor microenvironment of melanoma.Frontiers in immunology · 2026Article
- Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.Frontiers in oncology · 2026Review
- OX40L and IL-2 combination strategy for gastric cancer immunotherapy.Translational cancer research · 2025Article
- Oncolytic virus-induced IL-1βJournal for immunotherapy of cancer · 2025Article
- Soil and Seed: Tumor Microenvironment Nurtures Immunotherapy Resistance and Renewal.International journal of molecular sciences · 2025Review
- Oncolytic herpes simplex virus reprograms cancer-associated fibroblasts to enhance antitumor immunity in pancreatic cancer.Molecular therapy. Oncology · 2025Article
- Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Shiyu LiuState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Fan LiState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Qiongqiong MaState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Mingjuan DuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Haoran WangState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Yiping ZhuState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Li DengCNBG-Nankai University Joint Research and Development Center, Tianjin, China.
Wenrui GaoCNBG-Nankai University Joint Research and Development Center, Tianjin, China.
Chunlei WangState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Yanqin LiuState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Zhuoqian ZhaoState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Huanzhen LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Ruikun WangState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Yujie TianState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Manli HuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Yajuan WanState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Wenyi LuDepartment of Hematology, Tianjin First Central Hospital, Tianjin 300192, China.
Meng ZhangDepartment of Hematology, Tianjin First Central Hospital, Tianjin 300192, China.
Mingfeng ZhaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin 300192, China.
Youjia CaoState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Hongkai ZhangState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Wei WangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Hui WangCNBG-Nankai University Joint Research and Development Center, Tianjin, China.
Yuan WangState Key Laboratory of Medicinal Chemical Biology and College of life science, Nankai University, Tianjin, China.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Pancreatic DuctalOncolytic VirotherapyOncolytic VirusesPancreatic NeoplasmsAnimalsMiceMice, Inbred C57BLTumor Microenvironmentoncolytic virusOX40Lpancreatic cancerT celltumor immune microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.